105 results about "Metabolic Process" patented technology

The invention relates to a method for identifying a disease microorganism-metabolite combined marker based on a host-flora co-metabolism model. The method comprises the following steps: processing microbiome data; setting diet constraint conditions; determining classification composition of intestinal microorganisms of each individual, mapping abundance of each microorganism to a human microorganism genome scale metabolism model, and constructing an individualized flora metabolism network model; carrying out metabolic flow simulation on the constructed flora metabolism network model; integrating the constructed flora metabolism network model with the host metabolism network model, and predicting the metabolic flow and metabolite change of the whole system; and establishing a disease classifier based on a random forest machine learning algorithm to identify the microorganism-metabolite combined marker. According to the method, the complex metabolic process between the human body and the intestinal flora is restored in a metabolic network modeling and metabolic flow simulation mode, the method has the non-invasive characteristic, the time and economic cost is remarkably reduced, and meanwhile, the method has a great advantage in accuracy.

The invention provides a Burkholderia paradensis (Paraburkholderia caledonica) and an application of the Burkholderia paradonica (Paraburkholderia caledonica). The strain provided by the invention can realize green and efficient recovery of various rare earth raw materials. According to the present invention, the bacterial strain can produce a variety of organic acids and secondary metabolites having complexing properties during the metabolism process, and the electron transfer process on the surface of the microbial cell membrane provides important effects in the leaching of different rare earth raw materials;

The invention discloses a method for producing MK-7 through whole-cell regulation and control by using different time sequence type promoters, recombinant escherichia coli and application. According to the method, the time sequence type promoters are used for regulating and controlling expression of different key genes related to MK-7 synthesis. According to the invention, the time sequence promoter is used for whole-cell regulation and control to produce the vitamin MK-7 for the first time, dynamic regulation of the MK-7 is realized, and the production efficiency of the MK-7 can be remarkably improved by accurately regulating and controlling expression of key genes in a synthesis route of the MK-7 and optimizing an intracellular metabolic process. The promoter disclosed by the invention can regulate cell metabolism and enhance synthesis of MK-7 in different growth stages or under different environmental conditions by controlling the time and strength of gene expression. The MK-7 is produced by adopting the constructed recombinant escherichia coli obtained based on whole-cell regulation of the sequential promoter, and the yield of 14 g / L can be finally achieved in a 5L fermentation tank.

The invention discloses a screening and expression platform construction method for non-essential gene loci of corynebacterium glutamicum, and belongs to the technical field of biology. The center sites CGLRS02940, CGLRS03085, CGLRS08555, CGLRS09020 and CGLRS13560 of the corynebacterium glutamicum identified by the invention have the remarkable advantages that when gene knockout or knockin operation is carried out, the sites do not interfere with the normal physiological metabolism process of strains, and stable expression of exogenous genes can be guaranteed; meanwhile, the gene editing efficiency is relatively high, and an editing target with high universality and high reliability is provided for genetic engineering modification of corynebacterium glutamicum.

The present invention relates to the field of biomedicine technology, and provides the use of an upregulator of ACOT2 in promoting liver regeneration and liver function recovery after partial hepatectomy. Specifically, it provides the use of an ACOT2 expression promoter in the preparation of a drug for promoting liver regeneration and liver function recovery after partial hepatectomy, as well as a pharmaceutical composition comprising the ACOT2 expression promoter. The present invention has developed new discoveries about the function of the ACOT2 gene. The increased expression of ACOT2 after hepatectomy has a certain protective effect on liver regeneration, or can serve as a potential marker for warning the degree of postoperative liver function damage and liver regeneration capacity, and a therapeutic target for promoting postoperative liver regeneration. By using the intervention method of the present invention, the decomposition and consumption of lipid droplets in the liver lipid metabolism process are targeted, thereby promoting the recovery of liver function and liver-to-body ratio.

The present invention provides a Bacillus tequilensis ZW-35 and its application, which relates to the technical field of microbial control. The Bacillus tequilensis ZW-35 is preserved in the China General Microbiological Culture Collection Center, and its taxonomic name is Bacillus tequilensis Bacillus tequilensis , and the preservation number is CGMCC No. 32878. The volatile substances in the metabolic process of Bacillus tequilensis ZW-35 can effectively inhibit the growth of Colletotrichum; and the volatile substances have high diffusion ability in air and soil pores. In the prevention and control of fruit diseases, the volatile substances can avoid direct contact with the fruits and will not leave residues on the fruit surface, thus avoiding the potential risks brought by direct contact.

The application discloses an Akkermansia muciniphila branched-chain amino acid metabolism gene nifJ and application thereof in colostrum IgA synthesis, and belongs to the technical field of genetic engineering. The application finds through in-vivo and in-vitro tests that the nifJ is a branched-chain amino acid metabolism gene of the Akkermansia muciniphila, regulates the metabolism process from branched-chain amino acids to branched-chain short-chain fatty acids, and plays a key role in the synthesis of maternal colostrum IgA. The research result of the application is expected to clarify the interaction relationship between the metabolic function of the Akkermansia muciniphila and a host, and reveal the action mechanism of the Akkermansia muciniphila in regulating the synthesis of maternal colostrum IgA, thereby providing a theoretical basis for improving the maternal colostrum IgA and further improving the maternal reproductive performance.

The invention provides a screening method of a targeted drug for inhibiting accumulation of trimethylamine and / or trimethylamine-N-oxide. The screening method comprises the following steps: determining an action target on a metabolic pathway of trimethylamine and / or trimethylamine-N-oxide; if the target is protein, preliminarily screening candidate components based on the three-dimensional structure of the target; the candidate component is validated to confirm the targeted drug. According to the method, large-scale screening of targeted drugs aiming at targets can be achieved, the targeted drugs inhibit accumulation of trimethylamine and / or trimethylamine-N-oxide in the body by influencing the metabolic pathway of trimethylamine and / or trimethylamine-N-oxide, side effects are small, and the normal metabolic process of the human body is prevented from being influenced.

The invention discloses a broad-spectrum plant-source disease-resistant excitant for rice blast and a preparation method thereof, and belongs to the technical field of rice blast prevention and control, in the broad-spectrum plant-source disease-resistant excitant, potassium glutamate serves as amino acid salt, not only provides a nitrogen source for plants, but also participates in the metabolic process in the plants and enhances the stress resistance of the plants. S-allyl-L-cysteine is a sulfur-containing amino acid derivative, has antioxidant and disease-resistant activity, and can stimulate a defense mechanism of plants and resist infection of magnaporthe oryzae. 2-piperidinecarboxylic acid has the effect of inhibiting growth of pathogenic bacteria and can directly interfere with cell wall synthesis of magnaporthe oryzae, so that diseases are relieved. Chitosan as a biological polysaccharide can induce plants to generate resistant substances, enhance the strength of plant cell walls, form a physical barrier and prevent invasion of pathogenic bacteria. Salicylic acid is an important signal molecule in a plant body and can activate systematic resistance of the plant and improve the overall disease resistance.

The utility model relates to the technical field of medical detection equipment, in particular to an in-vitro micro-tissue drug metabolism detection device. Comprising an incubation chamber, a printing terminal and an auxiliary assembly, a temperature control assembly is arranged at the top of the incubation chamber, the auxiliary assembly comprises a first conveyor, a second conveyor, a sorting robot, a sample pool and a detection component, the incubation chamber is used for incubating samples, the incubated samples are placed on the first conveyor to be conveyed, and after being detected by the detection component, the samples are sent to the printing terminal. After detection, samples can be rapidly placed on the second conveyor to be conveyed, finally, the samples are placed into the sample pools at different positions through the sorting robot according to feedback information of the control system, the printing terminal can print and output detection data, then the in-vivo microenvironment can be simulated, the in-vivo metabolic process of drugs can be accurately simulated, and the in-vivo microenvironment can be simulated. Moreover, preliminary detection and rapid transfer of samples can be realized, and the detection efficiency can be improved.

The application discloses an activated persulfate catalyst and a preparation method and application thereof, and relates to the technical field of catalysts.The catalyst is a bismuth-carbon intercalation catalyst in a chain structure, and the preparation method comprises the following steps: S1, taking a bismuth salt and an acyl benzene ligand as reaction substrates, and synthesizing Bi-MOFs through a hydrothermal reaction; and S2, calcining the Bi-MOFs at 500-700 DEG C under an inert gas atmosphere to obtain the bismuth-carbon intercalation catalyst.The bismuth-carbon intercalation catalyst activates persulfate through a non-radical direct electron transfer path, has higher activity and selectivity, can more effectively sterilize and disinfect specific structures and metabolic processes of target microorganisms, and improves the treatment efficiency; and can reduce the generation of by-products, effectively reduces the risk of the environment and the human body.

The invention discloses a high-yield cell-free protein synthesis system based on a cell crude extract and application of the high-yield cell-free protein synthesis system. The system comprises an escherichia coli extract, a DNA template, a buffer solution, an amino acid mixture, a nucleoside triphosphate mixture, an ATP regeneration system and antibiotics, the antibiotics are selected from compounds having inhibitory activity on metabolic processes except ribosome functions in prokaryotic microorganisms, including but not limited to one or more combinations of interfering DNA replication, DNA transcription, cell wall synthesis, energy metabolism, lipid synthesis or other non-translational related metabolic pathways. According to the method disclosed by the invention, the escherichia coli crude extract is used as a bacterial chassis, and non-essential metabolic pathways in a CFPS system are selectively inhibited by introducing different types of antibiotics, so that the yield of protein synthesis is increased.

The invention belongs to the technical field of drug toxicity prediction, and particularly relates to a drug toxicity prediction method based on metabolism guidance. The invention aims to guide a prodrug or a non-toxic substance through a metabolism method and consider the toxicity of the prodrug or the non-toxic substance in the metabolic process (for example, the prodrug is converted into an effective component in the metabolic process), so as to predict the potential toxicity of the prodrug or the non-toxic substance. By means of the guidance of metabolism, it is desirable to accurately predict whether or not a prodrug will generate toxicity in the body. In the technical scheme provided by the invention, molecules are learned by using different characterization modes for the molecular map, so that different features under different levels and different segmentation methods can be captured. Through the guidance of the metabolic diagram, the reactants can obtain product-related attributes for explaining the toxicity change generated in the metabolic process of the reactants.

The application discloses a method for dynamically regulating the content of smell and taste substances in the secondary metabolism process of streptomyces, and relates to the technical field of molecular biology. The method for dynamically regulating the content of smell and taste substances in the secondary metabolism process of streptomyces disclosed by the application determines a first promoter and an sgRNA sequence capable of targeting a first target gene affecting the synthesis of a target compound according to the types of microorganisms and the target compound; a first recombinant plasmid is constructed by using a molecular cloning method; meanwhile, a second promoter for starting the synthesis of the target compound and a gene sequence capable of encoding a Cas protein losing cutting activity are determined, and the two are connected to obtain a regulation unit; the linearized enzyme cutting product after double enzyme cutting of the first recombinant plasmid is connected with the regulation unit to obtain a time-sequential dynamic inhibition recombinant plasmid, and after the recombinant plasmid is introduced into streptomyces, a streptomyces strain with reduced content of smell and taste (geosmin) substances in the secondary metabolism process is obtained.

The application discloses a non-natural sugar and a synthesis method and application thereof. At room temperature, hydroxyl groups of an amino sugar are fully trimethylsilyl-protected, amino groups on the sugar are selectively exposed, and after coupling and conversion of the amino groups at room temperature, a non-natural sugar with orthogonal groups and full trimethylsilyl protection is obtained. The non-natural sugar with orthogonal groups and full trimethylsilyl protection is removed from trimethylsilyl protection groups, and a non-natural sugar without protection groups is obtained. The application takes into account the advantages of existing non-natural sugars, ensures that the non-natural sugars can be efficiently utilized by cells, effectively avoids S side reactions with cysteine in proteins in the metabolic process of the non-natural sugars, and simultaneously realizes efficient metabolic labeling. In a cell test, the use concentration of 1,6-bisacylated non-natural sugar is one order of magnitude lower than that of non-natural sugar without protection groups.

The invention discloses a multi-gene tandem recombinant strain as well as a construction method and application thereof. The invention also discloses a method for synthesizing lycopene based on an isopentenol utilization approach. The strain comprises a recombinant strain of seven key genes, namely mtipk, thim, ispA, idi, crtE, crttheB and crtI, for synthesizing lycopene in an IUP (Inhibitory Urinary Protein) way. According to the invention, the isopentenol is introduced into the escherichia coli in a way to synthesize the lycopene; according to the approach, only two-step phosphorylation reaction is used for replacing the original 2-C-methyl-D-erythritol-4-phosphoric acid approach and mevalonic acid approach which need more than seven steps to synthesize precusor substances pentadienyl pyrophosphoric acid and dimethyl allyl pyrophosphate ester of lycopene, so that the metabolic pathway is greatly shortened, and competition with central carbon metabolism in cells is avoided; the toxicity caused by accumulation of intermediate products in the metabolic process is reduced, and lycopene can be efficiently synthesized by using a cheap substrate.

The present invention relates to the field of biomedicine technology, and in particular to a dynamic fermentation tank control system for the production of diabetic intestinal microecological regulation preparations. The system includes a fermentation tank sensor feedback control network establishment module, a fermentation tank growth early stage nutrient supply control module, a fermentation tank growth late stage regulation control module, and a fermentation tank metabolic process environmental condition control module. An embedded sensor feedback control network can be generated by installing sensors and connecting to a central feedback control system, and synchronously monitoring the sugar source supply, nitrogen source supply, temperature, pH value, dissolved oxygen concentration, and oxygen and carbon dioxide gas ratio flow rate corresponding to the fermentation tank in real time to perform supply coordinated dynamic control and fermentation growth coordinated dynamic control, while performing metabolic environmental condition coordinated dynamic control to perform microbial growth environmental condition coordinated control work. The present invention can achieve efficient production of intestinal microecological regulation preparations by optimizing environmental control during the fermentation process.

The invention belongs to the technical field of analysis and detection, and particularly relates to a preparation method and application of a matrix-assisted laser desorption ionization tandem time-of-flight mass spectrometry plant sample, the preparation method of the plant sample created by the invention can separate leaf inner epidermis and mesophyll tissue, and the leaf inner epidermis and mesophyll tissue are utilized to research metabolites in leaves. After the inner epidermis and mesophyll of the leaf are separated, not only can organic acid, small molecular compounds and macromolecular substances in the leaf be detected, but also the change of the content of the organic acid can be revealed. According to the MALDI mass spectrometry technology, assimilation of NH4 < + > / NO3 <-> in leaf inner epidermis or mesophyll tissue can be monitored in an imaging mode, so that the metabolic process of nitrogen is visualized; in the nitrogen metabolism process, NH4 < + > is directly used for synthesizing amino acid, NO3 <-> is reduced into NO2 <->, and NO2 <-> is assimilated into amino acid and derivatives thereof. The preparation method provided by the invention has unique advantages, and is beneficial to deeply understanding the metabolic process and biological functions of plants.

The invention provides a covalent complex of human milk oligosaccharide and a fluorescent reagent and a preparation method of the covalent complex, and belongs to the field of organic chemistry. The application of the human milk oligosaccharide-cyanine dye Cy7 covalent complex provided by the invention in monitoring the metabolic distribution of the human milk oligosaccharide-cyanine dye Cy7 covalent complex in internal tissues and organs through fluorescence imaging has a good tracing effect, and can dynamically trace the metabolic process of human milk oligosaccharide in vivo at different time points; compared with a traditional liquid chromatography-mass spectrometry in-vitro drug metabolism detection method, the fluorescence tracing method has the advantage that the in-vivo metabolism condition of the human milk oligosaccharide can be accurately, intuitively and efficiently monitored.

The present application relates to novel compounds that are prodrugs of brexpiprazole. The novel compounds of the present invention, upon administration to a subject, undergo chemical conversion by one or more metabolic processes to release the active agent in vivo. Brexpiprazole sold by Rexulti (registered trademark) is an atypical antipsychotic drug, is suitable for being used as an adjuvant therapy of an antidepressant drug, and is used for treating major depressive disorder (MDD) of adults and schizophrenia of adults and children patients over 13 years old. # imgabs0 #

The invention discloses a cinnamomum camphora MYB transcription factor gene, and belongs to the technical field of forest metabolism regulation. The nucleotide sequence of the gene is as shown in SEQ ID NO.5. The amino acid sequence of the transcription factor is as shown in SEQ ID No.7. The gene provided by the invention is one of key genes in a cinnamomum camphora metabolism process, and can regulate and control flavonoid metabolism, terpenoid metabolism, organic acid metabolism and the like of cinnamomum camphora. The gene provides an important theoretical basis for the industrial production in the fields of cinnamomum camphora breeding, medicines, spices and the like in the future, and has a wide application prospect and a great economic value.

The invention provides new application of an ATOX1 gene and ATOX1 protein, and belongs to the technical field of treatment of vitiligo diseases. The ATOX1 gene serving as a key gene of copper metabolism is disclosed for the first time, and melanin synthesis is promoted by activating the melanocyte copper metabolism process, so that the effect of resisting leucoderma is achieved. The ATOX1 gene and / or the ATOX1 protein can be used as a key biomarker in the vitiligo morbidity process, and a new target and a new molecular basis are provided for vitiligo research.

The invention belongs to the field of biomedical technology, and specifically relates to a pharmaceutical composition for preventing / treating Alzheimer's disease. The present invention proposes a pharmaceutical composition based on the NPAFP protein, which can play a role at multiple pathological levels by utilizing the synergistic effect of natural and synthetic compounds, and significantly improve the symptoms of AD. The composition has significant antioxidant, anti-inflammatory, promoting Aβ clearance, improving mitochondrial quality, reducing the pathological state caused by Aβ42 secretion and Tau PFF, etc., and can protect neurons by regulating the metabolic process. By screening and optimizing compounds with synergistic effects and further clarifying their mechanism of action, a new safe and efficient potential solution for the treatment of AD is provided, with broad clinical application prospects. The drug has high safety, strong specificity, a simple preparation method, and can be mass-produced.

A process is disclosed for production of a polyhydroxyalkanoate that includes depolymerization of a post-consumer polyhydroxyalkanoate and utilization of the hydroxyalkanoate monomer thus produced as a carbon source for a microorganism capable of production of a polyhydroxyalkanoate. Methods can be utilized for true cyclic use of polyhydroxyalkanoates including polyhydroxybutyrates. Various aspects are described including simultaneous depolymerization and polymer production, utilization of purified depolymerase enzymes and / or microorganisms that express a depolymerase in conjunction with a microorganism that produces polymer, utilization of microorganisms that produce both a depolymerase and a new polymer, and utilization of genetically modified organisms to produce natural or modified depolymerase enzymes.

This invention relates to a propofol administration method based on deep learning-based pharmacokinetic-pharmacodynamic and reinforcement learning methods and its application. It uses a PKPD model to simulate the metabolic process of propofol in the human body, extracts time-dependent and kinetic continuous information through LSTM and Neural OED, and then establishes a nonlinear relationship between the effective concentration of propofol and the clinically observed anesthesia depth index (BIS) using a Kan network. This rapidly establishes a mapping between intraoperative monitoring information and anesthesia depth, allowing for timely adjustments to the strategy based on environmental changes. It is suitable for handling non-standardized and complex problems, enabling personalized adjustments to drug dosage and administration regimens, and improving therapeutic efficacy.

The utility model provides a biological metabolism process control system, and belongs to the technical field of biological metabolism control systems.The biological metabolism process control system comprises a culture unit, the culture unit is a bioreactor, the culture unit is connected with a detection unit and an information processing unit, and the bioreactor is composed of a tank body, a tank cover, a base, a stirring device, a heating device and a ventilation device; the detection unit is composed of a first detection module and a second detection module, and the first detection module is composed of a mechanical motion structure, a sample collection structure, a sample treatment structure, an OD detection structure, an ion detection module and an enzyme membrane reaction tank structure; the second detection module is composed of a pipetting structure, a heating oscillation structure, a mechanical motion structure and an optical structure. The problems that an existing control system is large in workload, cannot effectively feed back and adjust metabolism of strains and is single in function are solved.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to application of a qi-tonifying and blood-maintaining preparation in preparation of a medicine for treating thalassemia. Researches show that the preparation for tonifying qi and maintaining blood is used for treating thalassemia and can effectively improve the anemia state and iron metabolism disorder of patients. Specifically, the medicine can significantly improve the hemoglobin level, increase the red blood cell count and the red blood cell average volume, and improve the serum iron content, the ferritin content and the reticulocyte proportion. The results show that the qi-tonifying and blood-maintaining preparation has the effect of promoting the bone marrow hematopoiesis function and can regulate and optimize the iron metabolism process. The invention provides an economical, effective and convenient treatment scheme for the thalassemia patient.

The invention provides a herbal medicine composition and a preparation for optimizing cell viability and resisting aging. The herbal medicine composition comprises the following components in percentage by weight: 5%-80% of a rhizoma polygonati extract, 5%-80% of a radix asparagi extract, 5%-80% of a pleurospermum tibetanum extract, 5%-80% of a mirabilis himalaica extract and 5%-80% of a tribulus terrestris extract. The herbal composition has a compound that protects cells from oxidative damage, enhances the cell repair mechanism, and improves the metabolic process with age decline; the composition is beneficial to optimization of cell activity and anti-aging, has wide benefits in anti-inflammatory, anti-oxidation, adaptability and other effects, is used for supporting overall activity, relieving pressure and enhancing immune function, has relatively low side effect risk, and supports anti-aging in a more comprehensive and more balanced manner.

The invention discloses an active substance for repairing a cat sensitization type barrier and a preparation method and application thereof, and relates to the technical field of animal health care products. The cat feed additive comprises one or more of heartleaf houttuynia herb extract, green tea polyphenol, ginkgo leaf extract, glutamine, beta-glucan, linoleic acid, vitamin B6, vitamin B2 and the like, and the components jointly act on oxidative stress, inflammatory response and metabolic process of intestinal tracts and skin of cats. By measuring indexes such as inflammatory factors, oxidative stress and tight junction protein and combining in-vitro metabonomics and transcriptomics analysis, the pharmaceutical composition has remarkable effects in the aspects of oxidation resistance, inflammation resistance, mucosal barrier repair and the like. In addition, the invention also provides application of the active substance in preparation of food for repairing cat barrier dysfunction. Compared with the prior art, an effective health-care strategy can be provided, and cat barrier dysfunction can be remarkably repaired.

The invention discloses an Akkermansia muciniphila branched chain amino acid metabolism gene nifJ and an application of the Akkermansia muciniphila branched chain amino acid metabolism gene nifJ in synthesis of colostrum IgA (Immunoglobulin A), and belongs to the technical field of gene engineering. In-vivo tests and in-vitro tests find that nifJ is used as a branched chain amino acid metabolism gene of Akkermansia muciniphila, regulates and controls the metabolic process from branched chain amino acid to branched chain short-chain fatty acid, and plays a key role in synthesis of maternal colostrum IgA (Immunoglobulin A). The research result of the invention is expected to clarify the interaction relationship between the metabolic function of the Akkermansia muciniphila and the host, and reveal the action mechanism of the Akkermansia muciniphila for regulating and controlling the synthesis of the IgA of the maternal colostrum, thereby providing a theoretical basis for improving the IgA of the maternal colostrum and further improving the reproductive performance of the maternal.